pembrolizumab,IMM60
merck,Portage
['lung', 'melanoma', 'imm-60', '$ibb', '$xbi', 'portage']
$prtg portage biotech presents updated interim data for their lead inkt engager, imm-60, in a phase 1/2 trial for advanced melanoma and metastatic non-small cell lung cancer at the 2023 asco annual meeting. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt